Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. - Wikidata - awgldk - TriplyDB

Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.

Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.

http://www.wikidata.org/entity/Q36946766

about

The clinically relevant pharmacogenomic changes in acute myelogenous leukemia What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Enlarging the scope of cell-penetrating prenylated peptides to include farnesylated 'CAAX' box sequences and diverse cell types.Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma Discovery of geranylgeranyltransferase-I inhibitors with novel scaffolds by the means of quantitative structure-activity relationship modeling, virtual screening, and experimental validation.Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors.Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.

P2860

Q27014790-D320703F-5BD0-4E3C-84C8-601A726C8E2B Q33775647-755DEC62-6B82-406A-9407-E7FA5717A60C Q34056922-0BAF1D96-69B8-4C3D-BDDB-D1EFFF2F946C Q35525553-0ECA0862-7849-4EC9-A07D-D2A5117F1D21 Q35651754-8C05C26C-F358-4D43-99C4-22C5D76352E3 Q36968955-23553A65-EDB0-4455-B183-8855C504352F Q37304601-D3DBBCE4-A433-4E04-8A55-367E55D3A144 Q37355543-B4FE71DE-1852-4A74-8496-985F8DFCF958 Q37424389-92A62D33-D945-4495-8BE2-A89EB3A2884F Q37586897-D55E0470-58E0-4E55-8448-39D8A15DE1BF Q38445385-CD523423-4368-4DB9-99B7-61141EE3F4E9 Q39074628-8D789C59-7722-488E-8126-A333F15E603B

P2860

Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.

http://www.wikidata.org/entity/Q36946766

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Development of farnesyltransfe ...... s on hematologic malignancies.

@en

type

label

Development of farnesyltransfe ...... s on hematologic malignancies.

@en

prefLabel

Development of farnesyltransfe ...... s on hematologic malignancies.

@en

P1433

Q36946766-E377B7DC-6971-414D-B136-6B7FF053CE33

P1476

Q36946766-67851992-B312-4C64-B384-D235A1A5AFD4

P2093

Q36946766-28624852-5A4C-4F08-857A-DFCAB646D088

Q36946766-EDD7172F-6A4E-4C0E-B65C-2C2DFA697D64

P2860

Q36946766-00D68674-3399-4D63-8A40-864E6EF15725

Q36946766-04D864D8-28F2-49C3-8B16-09D8CC2D37DB

Q36946766-063CA9AC-D035-4AF3-93CD-E742830E3E17

Q36946766-0DAA1A35-9CB5-43D3-B6BD-50F1F7918AA1

Q36946766-10945872-7F33-434D-BD19-A7176D9649F6

Q36946766-15DA23E5-034F-4FD5-869D-B9C1FB12A29A

Q36946766-1AAC1C62-ABE2-4AA4-AEAE-DC437657192A

Q36946766-22DEC48C-013E-4B8B-B061-A30DBB96691C

Q36946766-3B6E1544-2A55-4BC0-B67A-37B2A034B22F

Q36946766-4425F1A2-1192-4E64-A7E9-B7EE1ABCB23C

P304

Q36946766-74873B89-B7FB-4568-BED5-4F99152ACF6A

P31

Q36946766-9E062FF2-F919-4A82-ACA8-19D30C36C07E

P356

Q36946766-27B8A9E9-18E1-4EA0-8EAE-1E32FD708128

P433

Q36946766-345EBFC0-D316-4CE6-91E4-B56F428C1A12

P478

Q36946766-A38C9CE3-1087-4612-A828-782B2944B34A

P577

Q36946766-30EB7411-98F3-4571-8F0A-3DF1D3C81483

P698

Q36946766-C23FA063-86D8-4294-874C-D013BABB87CF

P356

07357900701359437

P1433

Cancer Investigation

P1476

Development of farnesyltransfe ...... s on hematologic malignancies.

@en

P2093

Jeffrey E Lancet

http://www.w3.org/2001/XMLSchema#string

Judith E Karp

http://www.w3.org/2001/XMLSchema#string

P2860

Protein kinase A- and protein kinase C-regulated interaction of plectin with lamin B and vimentin

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

Proteins regulating Ras and its relatives

CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

Interactions among proteins involved in bud-site selection and bud-site assembly in Saccharomyces cerevisiae.

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.

P304

484-494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07357900701359437

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17882662

http://www.w3.org/2001/XMLSchema#string